651744-39-7

Basic information

• Product Name: diethyl 1-aMino-3-isopropyl-1H-pyrrole-2,4-dicarboxylate
• Synonyms: diethyl 1-aMino-3-isopropyl-1H-pyrrole-2,4-dicarboxylate
• CAS NO: 651744-39-7
• Molecular Formula: C₁₃H₂₀N₂O₄
• Molecular Weight: 268.3089
• Mol File: 651744-39-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: diethyl 1-aMino-3-isopropyl-1H-pyrrole-2,4-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: diethyl 1-aMino-3-isopropyl-1H-pyrrole-2,4-dicarboxylate(651744-39-7)
• EPA Substance Registry System: diethyl 1-aMino-3-isopropyl-1H-pyrrole-2,4-dicarboxylate(651744-39-7)

Safety Data

• Hazardous Substances Data: 651744-39-7(Hazardous Substances Data)

Upstream product

• 651744-38-6 diethyl 3-(propan-2-yl)-1H-pyrrole-2,4-dicarboxylate 
• 2999-46-4 Ethyl isocyanoacetate 
• 5137-55-3 Aliquat 336 

Downstream Products

• 651744-40-0 ethyl 5-isopropyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylate 
• 658084-80-1 ethyl 4-chloro-5-iso-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate 
• 658085-65-5 5-isopropyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carbonitrile 
• 658084-85-6 4-[[3-[(methoxyamino)carbonyl]-4-methylphenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester 
• 658084-83-4 4-[[2-fluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester 
• 658084-97-0 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)-5-isopropylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid 
• 658085-52-0 5-(6-(azidocarbonyl)-5-isopropylpyrrolo[2,1-f][1,2,4]triazin-4-ylamino)-2,4-difluoro-N-methoxybenzamide 
• 658084-87-8 4-[[2,4-fluoro-5-[(methoxyamino)carbonyl]phenyl]amino]-5-(1-methylethyl)pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester 

Relevant articles and documents

SUBSTITUTED PYRROLO TRIAZINE CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN EP3 RECEPTOR ANTAGONISTS

The invention relates to substituted pyrrole triazine carboxamide derivatives of formula (I) and to processes for their preparation, and also /to their use for preparing medicaments for the treatment and/ or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and diabetes, and also urogenital and ophthalmic disorders.

New dual inhibitors of EGFR and HER2 protein tyrosine kinases

A novel series of dual EGFR and HER2 inhibitors based on the pyrrolo[2,1-f][1,2,4]triazine nucleus is described. A general route toward their synthesis, which enables functionalization at multiple sites, has been developed. Biological evaluation in enzyma